Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses

Gynecologic Oncology

Volumn 73, Issue 1, 1999, Pages 56-61

  Zhang, Zhen ^c,f   Barnhill, Stephen D ^c   Zhang, Hong ^c   Xu, Fengji ^d   Yu, Yinhua ^a   Jacobs, Ian ^b   Woolas, Robert P ^e   Berchuck, Andrew ^g   Madyastha, K R ^c   Bast Jr , Robert C ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^c Horus Global HealthNet   (United States)

^d PEKING UNION MEDICAL COLLEGE   (China)

^e ROYAL LONDON HOSPITAL   (United Kingdom)

^f MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^g NONE

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 72-4 ANTIGEN; SIALIC ACID; TUMOR MARKER;

AREA UNDER THE CURVE; ARTICLE; ARTIFICIAL NEURAL NETWORK; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; FEMALE GENITAL TRACT TUMOR; GYNECOLOGIC CANCER; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

EID: 0032943201     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1999.5320     Document Type: Article

References (16)

1. Jacobs I, Bast RC: The CA125 tumor associated antigen: a review of the literature. Hum Reprod 4:1-12, 1989
2. Finkler NJ, Benacerraf B, Lavin PT, Wojciechowski C, Knapp RC: Comparison of serum CA 125, clinical impression, and ultrasound in the preoperative evaluation of ovarian masses. Obstet Gynecol 72(4):659-664, 1988
3. Piver MS, Hempling RE: Etiology and Screening of Ovarian Cancer, in Thompson JD, Rock JA, (Eds): TeLinde's Operative Gynecology Updates, Philadelphia, PA: Lippincott, 1993, pp. 1-13
4. Woolas RP, Conaway MR, Xu F, Jacobs IJ, Yu Y, Daly L, Davies AP, O'Briant K, Berchuck A, Soper JT, et al.: Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecol Oncol 59(1):111-116, 1995
5. Wei JT, Zhang Z, Barnhill SD, Oesterling JE: Understanding artificial neural networks and exploring their potential applications for the practicing urologist. Urology 52(2):161-172, 1998
6. Dybowski R, Weller P, Chang R, Gant V: Prediction of outcome in critically ill patients using artificial neural network synthesised by genetic algorithm. Lancet 347(9009):1146-1150, 1996
7. Forsstrom JJ, Dalton KJ: Artificial neural networks for decision support in clinical medicine. Ann Med 27(5):509-517, 1995
8. Hinton GE: How neural networks learn from experience. Sci Amer 267: 144-151, 1992
9. Bishop CM: Neural Networks for Pattern Recognition, Oxford: Oxford Univ Press, 1995
10. Zurada JM: Introduction to Artificial Neural Systems. St. Paul; PWS, 1992, pp 138-157
11. Urban N, Drescher C, Etzioni R, Colby C: Use of stochastic simulation model to identify an effective protocol for ovarian cancer screen. Control Clin Trials 18:251-270, 1997
12. Woolas RP, Xu FJ, Jacobs IJ, Yu YH, Daly L, Berchuck A, Soper JT, Clarke-Pearson DL, Oram DH, Bast RC Jr: Elevation of multiple serum markers in patients with stage I ovarian cancer. J Natl Cancer Inst 85(21):1748-1751, 1993
13. Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG: A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 97(10):922-929, 1990
14. Davies AP, Jacobs I, Woolas R, Fish A, Oram D: The adnexal mass: benign or malignant? Evaluation of a risk of malignancy index. Br J Obstet Gynaecol 100(10):927-931, 1993
15. Jacobs I, Stabile I, Bridges J, Kemsley P, Reynolds C, Grudzinskas J, Oram D: Multimodal approach to screening for ovarian cancer. Lancet 1(8580):268-271, 1988
16. Jacobs I, Davies AP, Bridges J, Stabile I, Fay T, Lower A, Grudzinskas JG, Oram D: Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. Br Med J 306(6884):1030-1034, 1993